11/3/2026

speaker
Graham
Conference Operator

Good day, and thank you for standing by. Welcome to the RVNES Q3 2026 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Jeff Boyle, Ambassador Relations. Please go ahead.

speaker
Jeff Boyle
Investor Relations

Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release with our third quarter 2026 financial results, which is available in the investors and media section of our website at ARVENIS.com. Joining us on the call today, we have Randy Teel, our president and CEO, Angela Cacace, our chief scientific officer, and Andrew Saik, our chief financial officer. Before we begin, I'll remind you that today's discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. These risks and uncertainties are outlined in today's press release and in the company's recent filing with the Securities and Exchange Commission, which I urge you to read. Our actual results may differ materially from what is discussed on today's call. A replay of this call, as well as today's press release and an updated corporate deck, will be available on the Investor and Media section of our website. And now I'll turn the call over to Randy Teel. Randy?

speaker
Randy Teel
President and Chief Executive Officer

Thanks, Jeff, and good morning, everyone. I'll start by reiterating our commitment to prioritizing investments in programs where emerging evidence supports the greatest potential for value creation, letting the data drive our capital allocation decisions. If we execute on that commitment, we believe our Venice can create important medicines for patients and significant long-term value for shareholders. We are entering an important period of clinical milestones that we believe will further define both our individual programs and the broader potential of our platform during the call all provide an overview of our portfolio and plans. Angela will share additional information on our clinical programs, and Andrew will give an overview of our finances and approach to capital allocation. I'll begin with ARV 393, our oral BCL6 degrader, and a great example of a program with strong scientific rationale for differentiation. BCL6 is a key driver of lymphoma biology, and we believe our ability to degrade this classically undruggable transcription factor could offer a differentiated approach to treating B and T cell lymphomas. We see the potential for our BCL-6 integrator to become a backbone of future treatment strategies as both a monotherapy and in combination with standards of care. This could include reducing, delaying, or sparing chemotherapy for patients. During the quarter, as we continued enrolling the monotherapy and combination cohorts of our Phase I trial, We submitted our initial monotherapy dose escalation data for presentation at the ASH conference in December. This will be the first of two data readouts for the program with a second readout expected in mid-2027. The first disclosure will focus on patients with T cell lymphomas where there are limited treatment options available. These data support our belief that ARV393 is an active degrader of BCL6 with the potential to be very competitive as we continue development. The data we share in 2027 will include a greater proportion of patients dosed at levels expected to reach efficacious exposures in B-cell lymphomas, more robust data on durability, and initial data from the combination with glufidamab, the first of our planned combination cohorts. I'll move next to ARV027, our first-in-class oral antigen receptor degrader targeting the root cause of spinal bulbar muscular atrophy, or SBMA, also known as Kennedy's disease. This to greater targets the polyglutamine repeat androgen receptor or PolyQAR, which is found in patients with this genetically defined disease. SBMA is an excellent disease where the PolyQAR aggregates and gains a toxic function, driving progressive muscle weakness and functional decline. By eliminating the toxic accumulation of PolyQAR in muscle, We have the potential to create the first-ever disease-modifying therapy for patients with this rare neuromuscular disease. The SBMA program is advancing through multiple dose cohorts in its Phase I trial, and we intend to share initial data from the Healthy Volunteer cohorts in the first half of 2027. We also intend to begin dosing patients with SBMA in the first half of 2027. If successful, We believe the Phase I data for this program will significantly de-risk the program, and we will begin discussions with health authorities about initiating a registration-enabling trial. I'll turn next to our first immuno-oncology degrader, ARV6723. By impacting the immune system beyond the ability of current IO therapies, we believe this first-in-class oral HBK1 degrader could become an important treatment for patients in three distinct ways. First, following a checkpoint inhibitor. Second, in combination with a checkpoint inhibitor. And third, in indications where checkpoint inhibitors have not shown benefit. Based on promising monotherapy and combination preclinical data, we initiated a phase one trial in the third quarter. Monotherapy dose escalation is ongoing, and we plan to initiate dosing in combination with pembrolizumab in the first half of 2027. HPK1 is a protein that dampens multiple parts of the cancer immunity cascade, and we believe that by removing it, our degrader has the potential to harness the body's natural tumor immunity to fight cancer. We look forward to providing initial data from this program in the second half of 2027. Rounding out our clinical progress, I'll next provide a brief update on current plans for our LRRK2 degrader, ARV102. Following scientific advice from CHMP, We're now prioritizing the initiation of a Phase 1b trial in the EU and the UK. Next month, we plan to submit clinical trial applications for a Phase 1b trial in patients with progressive supranuclear palsy, or PSP. Trial initiation is targeted for 2027. In parallel, we're in consultation with Japanese health authorities to inform potential development in Japan as part of a long-term global clinical strategy. In the US, We continue discussions with the FDA about the ongoing clinical hold of our IMD. Our current objective is now to include US sites in future trials after completing the Phase 1B trial in the EU and the UK. Last month, we reported additional and novel biomarker findings from our Phase 1 trial, including improvements in an objective and quantifiable measure of impaired eye movement associated with Parkinson's disease. The totality of evidence from our Phase 1 trial strengthens our belief in the potential of LRRK2 degradation to create novel clinical breakthroughs for patients with devastating neurodegenerative diseases. What's common across all of our programs is the scientific premise that by degrading the proteins that cause disease, we can create transformational treatments to address unmet patient needs. We are pursuing targets where removing the protein has the potential to change the treatment landscape and improve outcomes for patients. The progress we're making today is laying the foundation for the next wave of innovation at Arvinas and advancing our mission of delivering transformative medicines to patients. With that, I'll turn the call over to Angela. Angela?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API